1.
The Effects of Intermittent Fasting on Glycemic Control and Body Composition in Adults with Obesity and Type 2 Diabetes: A Systematic Review.
Vitale, R, Kim, Y
Metabolic syndrome and related disorders. 2020;(10):450-461
Abstract
The purpose of this study was to evaluate the effects of intermittent fasting on glycemic control and body composition in adults with obesity and type 2 diabetes. Although intermittent fasting has shown some promise in improving glucoregulatory indicators and body composition in adults with obesity, there is currently no systematic review evaluating these effects in adults with obesity and type 2 diabetes. A database search of PubMed, CINHAL, and MEDLINE identified five studies that met inclusion criterion. All studies were randomized controlled trials in adult subjects (n = 46-137) with type 2 diabetes and a body mass index of ≥30 kg/m2. Four different intermittent fasting regimens were reviewed. All fasting regimens revealed strong evidence to support intermittent fasting as a feasible diet to improve glycemia and body composition measures within 12-24 weeks. Follow-up 12-18 months after intermittent fasting did not show promising results for continued weight loss and improved glycemic control. The majority of the studies demonstrated insignificant differences between intermittent fasting and continuous energy restriction for measures of glycated hemoglobin a1c and body composition. More data on intermittent fasting in adults with obesity and type 2 diabetes are needed to determine its benefits within this patient population. Future research should include consistent fasting regimens and larger sample sizes to improve the reliability and generalizability of the data. Also, consistent follow-up after a fasting intervention may enhance long-term benefits and should be considered in future research.
2.
Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis.
Lee, S, Lee, H, Kim, Y, Kim, E
Scientific reports. 2019;(1):13296
Abstract
Glycemic variability (GV) has been an emerging target for preventing complications related to type 2 diabetes. For reducing GV, DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs (OADs), but systematic evaluation has yet to be existed. A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to evaluate the effect of DPP-IV inhibitors compared with other OADs, on GV as measured by mean amplitude of glycemic excursions (MAGE). Searches were conducted using Pubmed, EMBASE, and the Cochrane Library, from which eligible studies were retrieved; seven RCTs were included in the analysis. DPP-IV inhibitors were found to significantly reduce MAGE compared to other OADs (mean difference = -14.61; 95% CI = -19.00 to -10.21; p < 0.0001) without significant heterogeneity among sulfonylureas (mean difference = -14.93; 95% CI = -21.60 to -8.26; p < 0.0001). Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies (p = 0.006), although no differences in MAGE were found based on HbA1c values. These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients. However, further studies utilizing larger numbers of patients and longer-term follow-ups are needed.